Aurobindo Pharma USA secures FTC clearance for $250 million Lannett acquisition

Through the transaction, Aurobindo USA will expand its product portfolio in this segment while gaining a U.S.-based manufacturing facility

Punita Kumar-Sinha appointed Independent Director at Aurobindo Pharma USA

Seasoned governance expert and board leader brings extensive experience in strategic oversight, risk management, and corporate governance across multiple sectors

Aurobindo to acquire Lannett Company for Rs. 2,185 Cr

The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities

USFDA classifies Aurobindo Pharma Inc's warehouse as OAI

The USFDA has determined the inspection classification status of this warehousing facility as 'Official Action Indicated

Evive Biotech and Acrotech Biopharma receive FDA approval of Ryzneuta

Evive enters license agreement with Acrotech Biopharma to commercialize Ryzneuta in US

Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)